Dr Reddy’s Laboratories (DRL) has launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of Cymbalta (Duloxetine delayed-release capsules) in the US market. DRL’s ANDA is approved by the United States Food & Drug Administration (USFDA).
The Cymbalta brand and generic had US sales of approximately $5.04 billion MAT for the most recent twelve months ending in April 2014 according to IMS Health.
Dr Reddy’s Duloxetine delayed-release capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts.
EP News Bureau – Mumbai